Upper Limb Sensorimotor DeficitsRHB ClinicNCT06725784
Feasibility and Cost of Robot-assisted Upper Limb Rehabilitation With Different Levels of Supervision
A study testing ReHandyBot in people with Upper Limb Sensorimotor Deficits, run by Swiss Federal Institute of Technology at 2 sites in Switzerland.
Trial summary
Upper limb impairments are often a result of neurological or traumatic injuries (e.g., stroke, traumatic brain injuries). These impairments may decrease independence in performing activities of daily living, severely affecting patients' quality of life. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Upper Limb Sensorimotor Deficits
- What is being tested?
- ReHandyBot
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 2 sitesSwitzerland
- Study dates
- 4 Mar 2025to 30 Dec 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Informed Consent signed by the subject.
- Female and male patients between 18 and 90 years old
- Presence of an upper limb deficit derived from any disease or event that, according to the responsible clinicians, could be improved by therapy with ReHandyBot.
Who cannot join
- Pathologies that may interfere with the training with ReHandyBot.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland2 sites, 2 recruiting
- Recruiting
Clinica Hildebrand Centro di riabilitazione Brissago
Brissago, 6614
Daria Dinacci, Dr. med., 0041917868633, d.dinacci@clinica-hildebrand.ch
- Recruiting
Clinica Hildebrand Centro Ambulatoriale Lugano
Lugano
Daria Dinacci, 0041 91 786 89 69, d.dinacci@clinica-hildebrand.ch
About this study
Official title: Feasibility and Cost of Robot-assisted Upper Limb Rehabilitation With Different Levels of Supervision: an Interventional Study
Upper limb impairments are often a result of neurological or traumatic injuries (e.g., stroke, traumatic brain injuries). These impairments may decrease independence in performing activities of daily living, severely affecting patients' quality of life. Growing evidence shows that increasing upper limb therapy dose for patients could improve functional outcomes and prevent their long-term deterioration. However, due to limited resources (e.g., the number of therapists) and high rehabilitation-related costs, providing a higher therapy dose to patients is challenging, both in the clinic and after discharge, and finding new models of care is therefore critical.
Minimally supervised or unsupervised robot-assisted therapy (i.e., patients training with rehabilitation devices with minimal to no supervision of an external person) holds the promise of allowing an increase in therapy dose with little impact on the additional resources needed. Because of their ability to provide active support and measure a wide set of parameters, actuated (active) rehabilitation robots seem to be the best solution for this therapy setting. However, such devices are often complex to use and have never been extensively tested minimally or unsupervised. Consequently, the data available on their feasibility and cost-effectiveness is limited.
At the Rehabilitation Engineering Laboratory (RELab, ETH Zurich), we developed ReHandyBot, an actuated device for unsupervised upper limb therapy. The device has already been tested with stroke patients in an unsupervised setting, with positive results regarding usability and increase in therapy dose. The main goal of this project is, therefore, to investigate the feasibility and cost of our robot-assisted continuum of care model (i.e., from inpatient to ambulatory). Specifically, we aim to evaluate the feasibility of integrating ReHandyBot into the clinical routine and perform a preliminary cost-benefit analysis of supervised, minimally supervised, and unsupervised robot-assisted therapy. Furthermore, we will also gather data on the overall dose of robot-assisted therapy and the intensity of use of the device in a clinical and ambulatory setting.
Read the detailed description
The ReHandyBot is a platform for hand rehabilitation with two degrees of freedom, namely forearm pronation/supination and finger flexion/extension. This device allows performing exercises targeting somatosensation and motor functions. Different exercises are implemented using virtual reality and haptic feedback; the interaction forces between subjects and ReHandyBot are measured by force sensors in the handles, allowing the control of a virtual hand and the physical interaction with the virtual environment. Mechanical properties (e.g., size, stiffness) of the objects displayed in the virtual environment are rendered by the motion/force of the instrumented handles. The type and difficulty level of the exercises are patient-specific and are automatically adapted throughout the therapy.
The duration and frequency of the therapy sessions with ReHandyBot depend on the specific patient's needs and are set according to the therapist's instructions.
The main goals of this study are to:
(i) Evaluate the feasibility of integrating ReHandyBot into the routine of rehabilitation clinics and ambulatories.
(ii) Perform a cost-benefit analysis of supervised, minimally supervised, and unsupervised therapy with the device.
The secondary goals are to investigate:
(iii) The intensity of use of ReHandyBot by the facilities. (iv) The increase in therapy dose for the patients using the device minimally or unsupervised compared to usual care.
(v) The quantity and characteristics of patients who can train supervised, minimally, or unsupervised with the device.
(vi) Usability and user experience.
All the patients admitted to the clinic or ambulatory will be screened for participation in this study. Eligible patients will receive robot-assisted therapy sessions with the ReHandyBot in parallel to their conventional therapy program. During therapy with ReHandyBot, the patient sits comfortably on a chair in front of a screen and places the fingers of the impaired hand on the handles of the device.
The eligibility of the patients will be checked during the admission visit, after which, for eligible patients, a trial session with ReHandyBot will be scheduled. During the trial session, the supervising therapist will decide if the patient can really benefit from training with ReHandyBot, and if yes, the therapist will integrate supervised therapy sessions with the device into the therapy schedule of the patient. Then, during the supervised sessions, the therapist will use a checklist to decide if a patient can train minimally supervised (i.e., group sessions) or unsupervised. If this will be the case, the minimally or unsupervised therapy sessions will be added to the therapy schedule of the patient. The therapy sessions with ReHandyBot (e.g., frequency, duration) will be scheduled based on the therapist's instruction and may vary between patients, depending on their specific needs. On the day of the last session with ReHandyBot, patients will fill in questionnaires to rate its usability and user experience.
For each recruited patient, data regarding demographics, medical condition, clinical and cognitive assessments, therapy dose, and device data will be recorded on the CRF. Medical and assessment data will be data routinely collected at the clinic and ambulatory. We will not perform evaluations specifically for this study.
At the end of the study, data regarding costs, intensity of use, and device retention will be recorded.
- Conditions
- Upper Limb Sensorimotor Deficits
- Being tested
- ReHandyBot
- Keywords
- unsupervised therapy, robot-assisted rehabilitation, stroke, neurorehabilitation, orthopaedic rehabilitation, upper limb rehabilitation
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ReHandyBotDevice
The ReHandyBot is a platform for hand rehabilitation with two degrees of freedom, namely forearm pronation/supination and finger flexion/extension. This device allows performing exercises targeting somatosensation and motor functions. Different exercises are implemented using virtual reality and haptic feedback; the interaction forces between subjects and ReHandyBot are measured by force sensors in the handles, allowing the control of a virtual hand and the physical interaction with the virtual environment. Mechanical properties (e.g., size, stiffness) of the objects displayed in the virtual environment are rendered by the motion/force of the instrumented handles. The type and difficulty level of the exercises are patient-specific and are automatically adapted throughout the therapy.
The duration and frequency of the therapy sessions with ReHandyBot depend on the specific patient's needs and are set according to the therapist's instructions.
| Study group | Role | What they receive |
|---|---|---|
| ReHandyBot | Experimental | The therapy sessions with ReHandyBot (e.g., frequency, duration) will be scheduled based on the therapist's instruction and may vary between patients, depending on their specific needs. Receives: Device: ReHandyBot |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cost of ReHandyBot
Manufacturing costs of ReHandyBot and cost of its maintenance over the duration of the study in Swiss Francs (CHF). These costs are monitored by the manufacturer.
Measured: Monitored through study completion (expected duration: 5 years).
Cost of the clinical staff supporting therapy with ReHandyBot
Cost in Swiss Francs related to the clinical staff being present during the therapy sessions with ReHandyBot. This will be extrapolated from the software that the clinic uses to handle the schedules of the therapists. This cost is calculated by multiplying the number of therapy sessions with the device performed by the therapists of the clinic by the hourly rate of the therapists.
Measured: Monitored through study completion (expected duration: 5 years).
Number of supervised therapy sessions with ReHandyBot
Number of therapy sessions with ReHandyBot performed by the participants under the supervision of a therapist (i.e., 1-to-1 therapy sessions). This number is extrapolated from the software that the clinic uses to handle the schedules of the patients.
Measured: Monitored through study completion (expected duration: 5 years).
Number of minimally supervised therapy sessions with ReHandyBot
Number of therapy sessions with ReHandyBot performed by the participants under minimal supervision of a therapist (e.g., group sessions). This number is extrapolated from the software that the clinic uses to handle the schedules of the patients.
Measured: Monitored through study completion (expected duration: 5 years).
Number of unsupervised therapy sessions with ReHandyBot
Number of therapy sessions with ReHandyBot performed by the participants without the supervision of a therapist (i.e., the therapist is not present). This number is extrapolated from the software that the clinic uses to handle the schedules of the patients.
Measured: Monitored through study completion (expected duration: 5 years).
Patient-to-therapist ratio of the therapy sessions with ReHandyBot
Ratio of the number of patients to number of therapists present during the therapy sessions with ReHandyBot, where a higher ratio (i.e., multiple patients for one therapist) constitutes an economic benefit for the clinic. This ratio is extrapolated from the software of the clinic handling the schedules of patients and therapists.
Measured: Monitored through study completion (expected duration: 5 years).
Secondary outcomes (12)
Feasibility of integrating ReHandyBot into the routine of a rehabilitation clinic: adverse events
Feasibility of integrating ReHandyBot into the routine of a rehabilitation clinic assessed as the number of adverse events related to the device.
Measured: Monitored through study completion (expected duration: 5 years).
Feasibility of integrating ReHandyBot into the routine of a rehabilitation clinic: device deficiencies
Feasibility of integrating ReHandyBot into the routine of a rehabilitation clinic assessed as the number of device deficiencies.
Measured: Monitored through study completion (expected duration: 5 years).
Feasibility of integrating ReHandyBot into the routine of a rehabilitation clinic: usage
Feasibility of integrating ReHandyBot into the routine of a rehabilitation clinic assessed as the usage (i.e., number of therapy sessions) of the device over time (i.e., if the device is no longer used after a short period, it means that it was not feasible to integrate it into the clinical routine of patients and therapists).
Measured: Monitored through study completion (expected duration: 5 years).
Intensity of use of ReHandyBot
Intensity of use of ReHandyBot, assessed as the number of hours per day when the device is occupied by a patient.
Measured: Monitored through study completion (expected duration: 5 years).
Increase in therapy dose: minutes
The increase in therapy dose in minutes for the patients using ReHandyBot minimally or unsupervised compared to usual care.
Measured: From participant's recruitment (day 0) until discharge from the clinic (on average: after 4 weeks).
Increase in therapy dose: percentage
The increase in physical therapy dose in percentage for the patients using ReHandyBot minimally or unsupervised compared to usual care.
Measured: From participant's recruitment (day 0) until discharge from the clinic (on average: after 4 weeks).
Quantity of patients training with ReHandyBot
Quantity of patients training with ReHandyBot expressed as the percentage of patients training with the device out of the total patients admitted to the clinic.
Measured: Monitored through study completion (expected duration: 5 years).
Characteristics of patients training with ReHandyBot
Characteristics (e.g., age, diagnosis) of patients training with ReHandyBot compared to the patients who are not eligible or able to train with ReHandyBot.
Measured: Monitored through study completion (expected duration: 5 years).
Reason why patients eventually stop training with ReHandyBot
Reason why an eligible patient eventually stops training with the device (e.g., due to not liking the device).
Measured: From participant's recruitment (day 0) until the last session performed with the device (on average: 4 weeks).
Evolution of patient's satisfaction with robot-assisted therapy as assessed by a 5-point scale
A 5-point scale is presented by the robot at the end of each therapy session to measure patient's satisfaction with robot-assisted therapy.
Measured: Monitored over the whole protocol duration (i.e., from the first to the last therapy session with ReHandyBot, on average 4 weeks).
Usability as assessed by the System Usability Scale
Usability of the ReHandyBot measured with the System Usability Scale. The possible response options vary between 1 (strongly disagree) and 5 (strongly agree).
Measured: Measured after two weeks from the first therapy session with ReHandyBot performed by a participant.
User experience - Net Promoter Score
The Net Promoter Score consists of the question "How likely would you be to recommend therapy with ReHandyBot to another patient?". The possible response options vary between 1 (extremely unlikely) and 10 (extremely likely).
Measured: Measured after two weeks from the first therapy session with ReHandyBot performed by a participant.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2024
- Study start4 Mar 2025
- Primary completion30 Dec 2030 (estimated)
- Study completion30 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Upper Limb Sensorimotor DeficitsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Swiss Federal Institute of Technology
- Sponsor type
- University, hospital or other
- Collaborators
- Clinica Hildebrand Brissago
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06725784
- Sponsor's protocol ID
- RHB Clinic
- Acronym
- RHB Clinic
- Status last verified
- Sep 2026
- First submitted
- 28 Nov 2024
- Last updated
- 17 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility and Cost of Robot-assisted Upper Limb Rehabilitation With Different Levels of Supervision: an Interventional Study
- ClinicalTrials.gov ID
- NCT06725784
- Acronym / sponsor ID
- RHB Clinic / RHB Clinic
- Conditions
- Upper Limb Sensorimotor Deficits
- Keywords
- unsupervised therapy, robot-assisted rehabilitation, stroke, neurorehabilitation, orthopaedic rehabilitation, upper limb rehabilitation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Swiss Federal Institute of TechnologyUniversity, hospital or other
- Collaborators
- Clinica Hildebrand Brissago
- Study start
- 4 Mar 2025 (actual)
- Primary completion
- 30 Dec 2030 (estimated)
- Study completion
- 30 Dec 2030 (estimated)
- First posted
- 10 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Upper limb impairments are often a result of neurological or traumatic injuries (e.g., stroke, traumatic brain injuries). These impairments may decrease independence in performing activities of daily living, severely affecting patients' quality of life. Growing evidence shows that increasing upper limb therapy dose for patients could improve functional outcomes and prevent their long-term deterioration. However, due to limited resources (e.g., the number of therapists) and high rehabilitation-related costs, providing a higher therapy dose to patients is challenging, both in the clinic and after discharge, and finding new models of care is therefore critical.
Minimally supervised or unsupervised robot-assisted therapy (i.e., patients training with rehabilitation devices with minimal to no supervision of an external person) holds the promise of allowing an increase in therapy dose with little impact on the additional resources needed. Because of their ability to provide active support and measure a wide set of parameters, actuated (active) rehabilitation robots seem to be the best solution for this therapy setting. However, such devices are often complex to use and have never been extensively tested minimally or unsupervised. Consequently, the data available on their feasibility and cost-effectiveness is limited.
At the Rehabilitation Engineering Laboratory (RELab, ETH Zurich), we developed ReHandyBot, an actuated device for unsupervised upper limb therapy. The device has already been tested with stroke patients in an unsupervised setting, with positive results regarding usability and increase in therapy dose. The main goal of this project is, therefore, to investigate the feasibility and cost of our robot-assisted continuum of care model (i.e., from inpatient to ambulatory). Specifically, we aim to evaluate the feasibility of integrating ReHandyBot into the clinical routine and perform a preliminary cost-benefit analysis of supervised, minimally supervised, and unsupervised robot-assisted therapy. Furthermore, we will also gather data on the overall dose of robot-assisted therapy and the intensity of use of the device in a clinical and ambulatory setting.
Detailed description
The ReHandyBot is a platform for hand rehabilitation with two degrees of freedom, namely forearm pronation/supination and finger flexion/extension. This device allows performing exercises targeting somatosensation and motor functions. Different exercises are implemented using virtual reality and haptic feedback; the interaction forces between subjects and ReHandyBot are measured by force sensors in the handles, allowing the control of a virtual hand and the physical interaction with the virtual environment. Mechanical properties (e.g., size, stiffness) of the objects displayed in the virtual environment are rendered by the motion/force of the instrumented handles. The type and difficulty level of the exercises are patient-specific and are automatically adapted throughout the therapy.
The duration and frequency of the therapy sessions with ReHandyBot depend on the specific patient's needs and are set according to the therapist's instructions.
The main goals of this study are to:
(i) Evaluate the feasibility of integrating ReHandyBot into the routine of rehabilitation clinics and ambulatories.
(ii) Perform a cost-benefit analysis of supervised, minimally supervised, and unsupervised therapy with the device.
The secondary goals are to investigate:
(iii) The intensity of use of ReHandyBot by the facilities. (iv) The increase in therapy dose for the patients using the device minimally or unsupervised compared to usual care.
(v) The quantity and characteristics of patients who can train supervised, minimally, or unsupervised with the device.
(vi) Usability and user experience.
All the patients admitted to the clinic or ambulatory will be screened for participation in this study. Eligible patients will receive robot-assisted therapy sessions with the ReHandyBot in parallel to their conventional therapy program. During therapy with ReHandyBot, the patient sits comfortably on a chair in front of a screen and places the fingers of the impaired hand on the handles of the device.
The eligibility of the patients will be checked during the admission visit, after which, for eligible patients, a trial session with ReHandyBot will be scheduled. During the trial session, the supervising therapist will decide if the patient can really benefit from training with ReHandyBot, and if yes, the therapist will integrate supervised therapy sessions with the device into the therapy schedule of the patient. Then, during the supervised sessions, the therapist will use a checklist to decide if a patient can train minimally supervised (i.e., group sessions) or unsupervised. If this will be the case, the minimally or unsupervised therapy sessions will be added to the therapy schedule of the patient. The therapy sessions with ReHandyBot (e.g., frequency, duration) will be scheduled based on the therapist's instruction and may vary between patients, depending on their specific needs. On the day of the last session with ReHandyBot, patients will fill in questionnaires to rate its usability and user experience.
For each recruited patient, data regarding demographics, medical condition, clinical and cognitive assessments, therapy dose, and device data will be recorded on the CRF. Medical and assessment data will be data routinely collected at the clinic and ambulatory. We will not perform evaluations specifically for this study.
At the end of the study, data regarding costs, intensity of use, and device retention will be recorded.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ReHandyBot | Experimental | Device: ReHandyBotThe therapy sessions with ReHandyBot (e.g., frequency, duration) will be scheduled based on the therapist's instruction and may vary between patients, depending on their specific needs. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Informed Consent signed by the subject.
- Female and male patients between 18 and 90 years old
- Presence of an upper limb deficit derived from any disease or event that, according to the responsible clinicians, could be improved by therapy with ReHandyBot.
Key exclusion criteria (1 listed)
- Pathologies that may interfere with the training with ReHandyBot.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ReHandyBotThe ReHandyBot is a platform for hand rehabilitation with two degrees of freedom, namely forearm pronation/supination and finger flexion/extension. This device allows performing exercises targeting somatosensation and motor functions. Different exercises are implemented using virtual reality and haptic feedback; the interaction forces between subjects and ReHandyBot are measured by force sensors in the handles, allowing the control of a virtual hand and the physical interaction with the virtual environment. Mechanical properties (e.g., size, stiffness) of the objects displayed in the virtual environment are rendered by the motion/force of the instrumented handles. The type and difficulty level of the exercises are patient-specific and are automatically adapted throughout the therapy. The duration and frequency of the therapy sessions with ReHandyBot depend on the specific patient's needs and are set according to the therapist's instructions. | Device | ReHandyBot |
Primary outcome
Cost of ReHandyBot
Time frame: Monitored through study completion (expected duration: 5 years).
Manufacturing costs of ReHandyBot and cost of its maintenance over the duration of the study in Swiss Francs (CHF). These costs are monitored by the manufacturer.
Cost of the clinical staff supporting therapy with ReHandyBot
Time frame: Monitored through study completion (expected duration: 5 years).
Cost in Swiss Francs related to the clinical staff being present during the therapy sessions with ReHandyBot. This will be extrapolated from the software that the clinic uses to handle the schedules of the therapists. This cost is calculated by multiplying the number of therapy sessions with the device performed by the therapists of the clinic by the hourly rate of the therapists.
Number of supervised therapy sessions with ReHandyBot
Time frame: Monitored through study completion (expected duration: 5 years).
Number of therapy sessions with ReHandyBot performed by the participants under the supervision of a therapist (i.e., 1-to-1 therapy sessions). This number is extrapolated from the software that the clinic uses to handle the schedules of the patients.
Number of minimally supervised therapy sessions with ReHandyBot
Time frame: Monitored through study completion (expected duration: 5 years).
Number of therapy sessions with ReHandyBot performed by the participants under minimal supervision of a therapist (e.g., group sessions). This number is extrapolated from the software that the clinic uses to handle the schedules of the patients.
Number of unsupervised therapy sessions with ReHandyBot
Time frame: Monitored through study completion (expected duration: 5 years).
Number of therapy sessions with ReHandyBot performed by the participants without the supervision of a therapist (i.e., the therapist is not present). This number is extrapolated from the software that the clinic uses to handle the schedules of the patients.
Patient-to-therapist ratio of the therapy sessions with ReHandyBot
Time frame: Monitored through study completion (expected duration: 5 years).
Ratio of the number of patients to number of therapists present during the therapy sessions with ReHandyBot, where a higher ratio (i.e., multiple patients for one therapist) constitutes an economic benefit for the clinic. This ratio is extrapolated from the software of the clinic handling the schedules of patients and therapists.
12 secondary outcomes
Feasibility of integrating ReHandyBot into the routine of a rehabilitation clinic: adverse events
Time frame: Monitored through study completion (expected duration: 5 years).
Feasibility of integrating ReHandyBot into the routine of a rehabilitation clinic: device deficiencies
Time frame: Monitored through study completion (expected duration: 5 years).
Feasibility of integrating ReHandyBot into the routine of a rehabilitation clinic: usage
Time frame: Monitored through study completion (expected duration: 5 years).
Intensity of use of ReHandyBot
Time frame: Monitored through study completion (expected duration: 5 years).
Increase in therapy dose: minutes
Time frame: From participant's recruitment (day 0) until discharge from the clinic (on average: after 4 weeks).
Increase in therapy dose: percentage
Time frame: From participant's recruitment (day 0) until discharge from the clinic (on average: after 4 weeks).
Quantity of patients training with ReHandyBot
Time frame: Monitored through study completion (expected duration: 5 years).
Characteristics of patients training with ReHandyBot
Time frame: Monitored through study completion (expected duration: 5 years).
Reason why patients eventually stop training with ReHandyBot
Time frame: From participant's recruitment (day 0) until the last session performed with the device (on average: 4 weeks).
Evolution of patient's satisfaction with robot-assisted therapy as assessed by a 5-point scale
Time frame: Monitored over the whole protocol duration (i.e., from the first to the last therapy session with ReHandyBot, on average 4 weeks).
Usability as assessed by the System Usability Scale
Time frame: Measured after two weeks from the first therapy session with ReHandyBot performed by a participant.
User experience - Net Promoter Score
Time frame: Measured after two weeks from the first therapy session with ReHandyBot performed by a participant.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Upper Limb Sensorimotor Deficits
Recruiting
Effectiveness of Active Exploration of Simulated Textures for Sensorimotor Recovery
Stroke, Sensorimotor Impairment Affecting the Upper Limb
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ReHandyBot in people with Upper Limb Sensorimotor Deficits, run by Swiss Federal Institute of Technology at 2 sites in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Giada Devittori, Dr. (0041445107234, giada.devittori@hest.ethz.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cost of ReHandyBot (time frame: Monitored through study completion (expected duration: 5 years).). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026.